Learn how you can manage and alleviate your current side effects while actively working to prevent a relapse or secondary cancer using evidence-based, non-toxic therapies.
Click the orange button to the right to learn more.
The takeaway from the study discussed below is that being female normally lowers the risk for most cardiovascular events. However this is not true for women who have non-alcoholic fatty liver disease.
According to research, “Up to 80% of obese people have the disease” and “About 12 to 25% of people in the United States have NAFLD, while NASH affects between 2 and 5% of people in the United States.”
NAFLD therapies include diet, exercise, surgery and supplementation. The study linked at the bottom of this page talks about omega 3 fatty acids and its ability to improve liver fat in NAFLD.
I am both a cancer survivor and cancer coach. I take and recommend Life Extension Super Omega 3 EPA/DHA.
To learn more about non-toxic NAFLD please scroll down the page, post a question or comment and I will reply to you ASAP.
“Non-alcoholic fatty liver disease (NAFLD) is one of the types of fatty liver which occurs when fat is deposited (steatosis) in the liver due to causes other than excessive alcohol use. Non-alcoholic steatohepatitis (NASH) is the most extreme form of NAFLD. NAFLD is the most common liver disorder in developed countries.
“Women with nonalcoholic fatty liver disease saw significantly higher rates of subsequent cardiovascular events compared with men and saw them occur at a younger age…
Sex is such an important risk modifier that it’s included in all the calculators we use in daily practice to estimate someone’s risk of developing future cardiovascular events…” “It is known that in the general population, the female sex is protective for cardiovascular disease, which means that women are less likely than men to have cardiovascular events. What we found in this study is that this does not hold true in people who have NAFLD; we found that women with NAFLD are not more protected than men with NAFLD.”
Allen and colleagues culled 4,196 patients with NAFLD from the Rochester Epidemiology Project database and 15,786 controls. Mean patient age was 52 years, 52% were women, and median follow-up was 7 years...
The researchers identified 1,684 cardiovascular events. The risk for cardiovascular events was high among women but not in men. Among women,
Conclusions. In this meta-analysis, omega-3 PUFAs improved liver fat, GGT, TG, and HDL in patients with NAFLD/NASH. Therefore, n-3 PUFAs may be a new treatment option for NAFLD…